论文部分内容阅读
卵巢癌是妇科常见的恶性肿瘤,其死亡率居妇科恶性肿瘤之首,早期发现有助于提高患者的五年生存率。人附睾蛋白(HE4)属于蛋白酶抑制剂家族,是一种新的卵巢癌肿瘤标志物。HE4在卵巢癌组织中及患者血清中处于高表达状态。研究表明在早期诊断方面HE4比糖类抗原125(CA125)有更高的灵敏度和特异度,在疾病的治疗过程中可以预测肿瘤细胞减灭术的满意度及患者对铂类的反应,在卵巢癌的复发及预后的监测中HE4也有很大的临床应用价值。
Ovarian cancer is a common gynecological malignancy, the mortality rate of gynecological malignancies in the first, early detection helps to improve the patient’s five-year survival rate. Human epididymal protein (HE4), a protease inhibitor family, is a novel tumor marker of ovarian cancer. HE4 is highly expressed in ovarian cancer tissues and patient sera. Studies have shown that HE4 has a higher sensitivity and specificity than carbohydrate antigen 125 (CA125) in early diagnosis and predicts the satisfaction of tumor cytoreductive surgery and platinum response in the treatment of the disease. In the ovary HE4 also has great clinical value in the detection of recurrence and prognosis of cancer.